Effect of leucine-rich repeat kinase 2 (LRRK2) on protein synthesis

被引:3
|
作者
Kim, Hyejung [1 ]
Son, Ilhong [1 ,2 ]
Seol, Wongi [1 ]
机构
[1] Wonkwang Univ, InAm Neurosci Res Ctr, Sanbonro 321, Gunposi, Gyeonggido, South Korea
[2] Wonkwang Univ, Dept Neurol, Coll Med, Sanbon Med Ctr, Gunposi, Gyeonggido, South Korea
基金
新加坡国家研究基金会;
关键词
Protein synthesis; LRRK2; Parkinson's disease; G2019S; kinase; PARKINSONS-DISEASE; PHOSPHORYLATION; AUTOPHAGY; 4E-BP; P53;
D O I
10.1080/19768354.2017.1422803
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
Mutations in the leucine-rich repeat kinase 2 (LRRK2) cause Parkinson's disease (PD) in an autosomal dominant manner. Pathogenic mutations of LRRK2 such as G2019S and R1441C have been observed as common genetic causes of PD. Recently, LRRK2 has been reported to increase the reporter protein synthesis in both cap-dependent and -independent manners via phosphorylation of the ribosomal protein RPS15. In this study, we tested whether LRRK2 recombinant protein would directly increase protein synthesis using a well-defined in vitro coupled transcription/translation system. Addition of commercial full-length LRRK2 or GST-fused N-terminal-deleted LRRK2 recombinant proteins to the system showed no change of protein synthesis, as measured by luciferase reporter activity. In addition, the SUnSET assay to measure newly synthesized cellular proteins showed that G2019S overexpression had a minimal effect on the total protein amount. However, we confirmed the previous result that G2019S overexpression increased the amount of protein synthesized from an exogenous gene, Flag-VAMP2, which was transfected as a reporter, whereas there was no significant change in the amount of the Flag-VAMP2 mRNA. Inhibition of protein degradation showed that protein accumulation in the vector control was higher than that of the G2019S overexpression vector. Our results suggest that LRRK2 protein influences the amount of protein by inhibiting protein degradation rather than by directly stimulating translation.
引用
收藏
页码:15 / 21
页数:7
相关论文
共 50 条
  • [31] Preclinical Evaluation of Novel Positron Emission Tomography (PET) Probes for Imaging Leucine-Rich Repeat Kinase 2 (LRRK2)
    Chen, Zhen
    Chen, Jiahui
    Mori, Wakana
    Yi, Yongjia
    Rong, Jian
    Li, Yinlong
    Leon, Erick R. Calderon
    Shao, Tuo
    Song, Zhendong
    Yamasaki, Tomoteru
    Ishii, Hideki
    Zhang, Yiding
    Kokufuta, Tomomi
    Hu, Kuan
    Xie, Lin
    Josephson, Lee
    Van, Richard
    Shao, Yihan
    Factor, Stewart
    Zhang, Ming-Rong
    Liang, Steven H.
    JOURNAL OF MEDICINAL CHEMISTRY, 2024, 67 (04) : 2559 - 2569
  • [32] Discovery of potent and selective 5-azaindazole inhibitors of leucine-rich repeat kinase 2 (LRRK2) - Part 1
    Osbornea, Joanne
    Birchall, Kristian
    Tsagris, Denise J.
    Lewis, Stephen J.
    Smiljanic-Hurley, Ela
    Taylor, Debra L.
    Levy, Alison
    Alessi, Dario R.
    McIver, Edward G.
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2019, 29 (04) : 668 - 673
  • [33] P62/SQSTM1 is a novel leucine-rich repeat kinase 2 (LRRK2) substrate that enhances neuronal toxicity
    Kalogeropulou, Alexia F.
    Zhao, Jing
    Bolliger, Marc F.
    Memou, Anna
    Narasimha, Shreya
    Molitor, Tyler P.
    Wilson, William H.
    Rideout, Hardy J.
    Nichols, R. Jeremy
    BIOCHEMICAL JOURNAL, 2018, 475 : 1271 - 1293
  • [34] Dyskinesias in patients with Parkinson's disease: Effect of the leucine-rich repeat kinase 2 (LRRK2) G2019S mutation
    Yahalom, Gilad
    Kaplan, Natalie
    Vituri, Aya
    Cohen, Oren S.
    Inzelberg, Rivka
    Kozlova, Evgenia
    Korczyn, Amos D.
    Rosset, Saharon
    Friedman, Eitan
    Hassin-Baer, Sharon
    PARKINSONISM & RELATED DISORDERS, 2012, 18 (09) : 1039 - 1041
  • [35] Leucine-rich repeat kinase-2 (LRRK2) modulates paraquat-induced inflammatory sickness and stress phenotype
    Rudyk, Chris
    Dwyer, Zach
    Hayley, Shawn
    JOURNAL OF NEUROINFLAMMATION, 2019, 16 (1)
  • [36] Expression of leucine-rich-repeat-kinase 2 (LRRK2) during embryonic development
    Zechel, Sabrina
    Meinhardt, Andreas
    Unsicker, Klaus
    von Bohlen und Halbach, Oliver
    INTERNATIONAL JOURNAL OF DEVELOPMENTAL NEUROSCIENCE, 2010, 28 (05) : 391 - 399
  • [37] Transcriptional responses to loss or gain of function of the leucine-rich repeat kinase 2 (LRRK2) gene uncover biological processes modulated by LRRK2 activity
    Nikonova, Elena V.
    Xiong, Yulan
    Tanis, Keith Q.
    Dawson, Valina L.
    Vogel, Robert L.
    Finney, Eva M.
    Stone, David J.
    Reynolds, Ian J.
    Kern, Jonathan T.
    Dawson, Ted M.
    HUMAN MOLECULAR GENETICS, 2012, 21 (01) : 163 - 174
  • [38] Identification of protein phosphatase 2A as an interacting protein of leucine-rich repeat kinase 2
    Athanasopoulos, Panagiotis S.
    Jacob, Wright
    Neumann, Sebastian
    Kutsch, Miriam
    Wolters, Dirk
    Tan, Eng K.
    Bichler, Zoe
    Herrmann, Christian
    Heumann, Rolf
    BIOLOGICAL CHEMISTRY, 2016, 397 (06) : 541 - 554
  • [39] Investigation of leucine-rich repeat kinase 2
    Anand, Vasanti S.
    Reichling, Laurie J.
    Lipinski, Kerri
    Stochaj, Wayne
    Duan, Weili
    Kelleher, Kerry
    Pungaliya, Pooja
    Brown, Eugene L.
    Reinhart, Peter H.
    Somberg, Richard
    Hirst, Warren D.
    Riddle, Steven M.
    Braithwaite, Steven P.
    FEBS JOURNAL, 2009, 276 (02) : 466 - 478
  • [40] The development of inhibitors of leucine-rich repeat kinase 2 (LRRK2) as a therapeutic strategy for Parkinson's disease: the current state of play
    Azeggagh, Sonia
    Berwick, Daniel C.
    BRITISH JOURNAL OF PHARMACOLOGY, 2022, 179 (08) : 1478 - 1495